GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (FRA:LDBB) » Definitions » Net Income Including Noncontrolling Interests

H. Lundbeck AS (FRA:LDBB) Net Income Including Noncontrolling Interests : €360 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

H. Lundbeck AS's Net Income Including Noncontrolling Interests for the three months ended in Sep. 2024 was €104 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2024 was €360 Mil.

H. Lundbeck AS Net Income Including Noncontrolling Interests Historical Data

The historical data trend for H. Lundbeck AS's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Net Income Including Noncontrolling Interests Chart

H. Lundbeck AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 309.64 212.51 177.24 257.54 307.24

H. Lundbeck AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.65 17.98 134.92 103.17 104.21

H. Lundbeck AS Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €360 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

H. Lundbeck AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (FRA:LDBB) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
OCSE:STENO ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA XSWX:SDZ NSE:DIVISLAB HKSE:03692 SZSE:000538 NSE:TORNTPHARM VTRS BOM:500124 BOM:532321 TSE:4507 BOM:543904 BOM:500257 NBIX
Traded in Other Exchanges
HLBBF:USA HLUBF:USA HLUNBc:UK 0ABR:UK 0ND5:UK HLUN A:Denmark HLUN B:Denmark LUNB:Austria
Address
Ottiliavej 9, Valby, DNK, 2500
Website
https://www.lundbeck.com
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS Headlines

No Headlines